Inpharma Weekly

, Volume 1486, Issue 1, pp 14–14 | Cite as

Amrubicin + cisplatin “impressive” for untreated advanced SCLC

Clinical study


Lung Cancer Survival Rate Neutropenia Survival Time Median Survival 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 2005

Personalised recommendations